Switch theme
Sign up to access all valuation multiples
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
2019
1
Last FY Revenue n/a
LTM EBITDA -$15.0M
$197M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bright Minds Biosciences has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$15.0M.
In the most recent fiscal year, Bright Minds Biosciences achieved revenue of n/a and an EBITDA of -$2.7M.
Bright Minds Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bright Minds Biosciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$15.0M | XXX | -$2.7M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$12.0M | XXX | -$2.8M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$10.7M | XXX | -$2.8M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Bright Minds Biosciences's stock price is $33.
Bright Minds Biosciences has current market cap of $237M, and EV of $197M.
See Bright Minds Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $197M | $237M | XXX | XXX | XXX | XXX | $-1.46 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Bright Minds Biosciences has market cap of $237M and EV of $197M.
Bright Minds Biosciences's trades at n/a EV/Revenue multiple, and -30.4x EV/EBITDA.
Equity research analysts estimate Bright Minds Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bright Minds Biosciences has a P/E ratio of -22.2x.
See valuation multiples for Bright Minds Biosciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $237M | XXX | $237M | XXX | XXX | XXX |
| EV (current) | $197M | XXX | $197M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -13.1x | XXX | -30.4x | XXX | XXX | XXX |
| EV/EBIT | -16.4x | XXX | -35.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -22.2x | XXX | -45.5x | XXX | XXX | XXX |
| EV/FCF | -15.7x | XXX | -38.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBright Minds Biosciences's revenue per employee in the last FY averaged n/a, while opex per employee averaged $2.8M for the same period.
Bright Minds Biosciences's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bright Minds Biosciences's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Bright Minds Biosciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 393% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Race Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Supriya Lifescience | XXX | XXX | XXX | XXX | XXX | XXX |
| Ascentage Pharma Group | XXX | XXX | XXX | XXX | XXX | XXX |
| ST Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Alpha Cognition | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bright Minds Biosciences acquired XXX companies to date.
Last acquisition by Bright Minds Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Bright Minds Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Bright Minds Biosciences founded? | Bright Minds Biosciences was founded in 2019. |
| Where is Bright Minds Biosciences headquartered? | Bright Minds Biosciences is headquartered in United States of America. |
| How many employees does Bright Minds Biosciences have? | As of today, Bright Minds Biosciences has 1 employees. |
| Who is the CEO of Bright Minds Biosciences? | Bright Minds Biosciences's CEO is Mr. Ian McDonald. |
| Is Bright Minds Biosciences publicy listed? | Yes, Bright Minds Biosciences is a public company listed on NAS. |
| What is the stock symbol of Bright Minds Biosciences? | Bright Minds Biosciences trades under DRUG ticker. |
| When did Bright Minds Biosciences go public? | Bright Minds Biosciences went public in 2021. |
| Who are competitors of Bright Minds Biosciences? | Similar companies to Bright Minds Biosciences include e.g. Race Oncology, Supriya Lifescience, Ascentage Pharma Group, ST Pharm. |
| What is the current market cap of Bright Minds Biosciences? | Bright Minds Biosciences's current market cap is $237M |
| Is Bright Minds Biosciences profitable? | Yes, Bright Minds Biosciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bright Minds Biosciences? | Bright Minds Biosciences's last 12 months EBITDA is -$15.0M. |
| What is the current EV/EBITDA multiple of Bright Minds Biosciences? | Current EBITDA multiple of Bright Minds Biosciences is -13.1x. |
| What is the current FCF of Bright Minds Biosciences? | Bright Minds Biosciences's last 12 months FCF is -$12.6M. |
| What is the current EV/FCF multiple of Bright Minds Biosciences? | Current FCF multiple of Bright Minds Biosciences is -15.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
